title: Should chemotherapy response be evaluated separately in sequential chemotherapy-radiotherapy schedules in locally advanced nonsmall-cell lung carcinoma?
authors.affiliation: Institut Gustave-Roussy, Villejuif, France.
authors.forename: F
authors.initials: F
authors.lastname: Thomas
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: P
authors.initials: P
authors.lastname: Ruffié
authors.forename: P
authors.initials: P
authors.lastname: Baldeyrou
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D013997:Time Factors; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D008130:Lomustine; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine